Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 17/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22386619 | 0.98 | HTR1A (0.64) | HTR1ASLC6A4 | |
| SCHEMBL20868495 | 0.91 | SLC6A4 (0.70) | HTR1ASLC6A4ADRA2ADRD2ADRA2B | |
| SCHEMBL20868395 | 0.89 | SLC6A4 (0.67) | HTR1ASLC6A4ADRA2ADRD2ADRA2B | |
| SCHEMBL20868146 | 0.85 | HTR1A (0.77) | HTR1ASLC6A4 | |
| SCHEMBL22371677 | 0.84 | SLC6A4 (0.63) | HTR1ASLC6A4 | |
| SCHEMBL20868501 | 0.83 | HTR1A (0.77) | HTR1ASLC6A4 | |
| SCHEMBL27110354 | 0.82 | SLC6A4 (0.56) | HTR1ASLC6A4ADRA2AADRA2BADRA2C | |
| SCHEMBL22386616 | 0.81 | HTR1A (0.47) | HTR1ASLC6A4ADRA2ADRD2ADRA2B | |
| SCHEMBL16433155 | 0.79 | HTR1A (1.00) | HTR1A | |
| SCHEMBL20868349 | 0.79 | HTR1A (0.76) | HTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3687989-B1 | SUBSTITUTED PYRIMIDINE PIPERAZINE COMPOUND AND USE THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2024-02-28 | — | — | EP | disclosed |
| EP-3687989-B1 | SUBSTITUTED PYRIMIDINE PIPERAZINE COMPOUND AND USE THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2024-02-28 | — | — | EP | disclosed |
| US-11285153-B2 | Substituted pyrimidine piperazine compound and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-03-29 | — | — | US | disclosed |
| US-20200276196-A1 | SUBSTITUTED PYRIMIDINE PIPERAZINE COMPOUND AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-09-03 | — | — | US | disclosed |
| US-20200276196-A1 | SUBSTITUTED PYRIMIDINE PIPERAZINE COMPOUND AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-09-03 | — | — | US | disclosed |
| WO-2019062662-A1 | SUBSTITUTED PYRIMIDINE PIPERAZINE COMPOUND AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200276196-A1 | SUBSTITUTED PYRIMIDINE PIPERAZINE COMPOUND AND USE THEREOF | HTR5A, TPH1, HTR2C | HTR1A 5/4885SLC6A4 13/4885ADRA2A 178/4885 |
| US-11285153-B2 | Substituted pyrimidine piperazine compound and use thereof | HTR5A, TPH1, HTR2C | HTR1A 5/4885SLC6A4 13/4885ADRA2A 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.